{"Clinical Trial ID": "NCT00425672", "Intervention": ["INTERVENTION 1:", "Bras I", "Patients receive ONTAK IV on one hour on days 1 to 5. Treatment is repeated every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.", "* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *", "Flow cytometry: correlated studies", "Immunohistochemical staining method: correlative studies", "Enzymatic immunosorbent assay: correlated studies", "Analysis of laboratory biomarkers: related studies", "Analysis of protein expression: correlated studies"], "Eligibility": ["Incorporation criteria:", "Patients with advanced refractory breast cancer", "A progressive or relapsed disease after standard treatment", "Patients should have a measurable disease that may include, but is not limited to, bones; in particular, patients should have a measurable extraskeletal disease that can be accurately measured in at least one dimension such as >= 20 mm with conventional CT techniques or >= 10 mm with a CT spiral scan; a measurable (bidimensional) chest wall disease will also be allowed.", "Patients should be at least 14 days away from the last cytotoxic chemotherapy; patients on bisphosphonates are eligible", "Number of white blood cells (WBC) > 3.0 THOU/ul", "ANC > 1.0 THOU/ul", "Platelets >= 100 THOU/ul", "Serum creatinine level = < 2.0 mg/dL or creatinine clearance (calculated) >= 60 ml/min", "ALT/AST = < 2.0 x upper limit of normal", "Total bilirubin = < 1.5 x upper limit of normal", "Albumin >= 3.0 g/dL", "Subjects must have a performance rating (ECOG scale) = < 2", "Subjects should have recovered from major infections and/or surgical procedures and, in the opinion of the investigator, should not have a major concomitant medical disease excluding protocol treatment", "Men and women of childbearing potential should accept contraceptive use during the study and for one month after discontinuation of ONTAK therapy.", "- Exclusion criteria:", "Prior treatment with ONTAK (DAB389 IL-2) or DAB486 IL-2", "known history of hypersensitivity to diphtheria toxin or IL-2", "An active autoimmune disease", "\u2022 Known history of lung disease, except controlled asthma", "\u2022 Pre-existing or pre-existing history of cardiovascular disease as defined by the New York Heart Association (NYHA) Class III-IV", "Pregnant or lactating women"], "Results": ["Performance measures:", "The safety assessed by collecting the study toxicity as assessed by the CLCAE v3.0", "Subjects are monitored for the development of end organ lesions by evaluating adverse reactions with serum chemistry, liver function studies, serum albumin, complete blood count, symptom evaluation and physical examinations performed during each cycle up to 3 weeks after the final dose of ONTAK.", "Time: 7 days after the last dose of ONTAK", "Results 1:", "Title of the arm/group: Arm I", "Description of the arm/group: Patients receive ONTAK IV on one hour on days 1 to 5. Treatment is repeated every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.", "* * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * *", "Flow cytometry: correlated studies", "Immunohistochemical staining method: correlative studies", "Enzymatic immunosorbent assay: correlated studies", "Analysis of laboratory biomarkers: related studies", "Analysis of protein expression: correlated studies", "Total number of participants analysed: 15", "Type of measure: Number of participants", "Unit of measure: Participants 15,100.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/15 (6.67 per cent)", "\u2022 Severe nausea and vomiting 1/15 (6.67 per cent)"]}